Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Sept 2020

Al-Quteimat Osama M, Amer Amer M

Abstract excerpt

Lung cancer is a complex, genetically heterogeneous disease. It is the most common cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) represents the majority of the diagnosed lung cancer cases. Osimertinib is a new treatment option that demonstrated a superior efficacy over standard epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) or platinum-based chemotherapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Identifiers

PMID: 32525442
DOI: 10.1177/1078155220930285

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care.PMID 32525442Read ↗

Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.Semantic proximity Read ↗

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update.Semantic proximity Read ↗

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.Semantic proximity Read ↗

Osimertinib in Advanced EGFR-T790M Mutation-positive Non-small Cell Lung Cancer Patients Treated Within the Special Use Medication Program in Spain. OSIREX-spanish Lung Cancer GroupSemantic proximity Read ↗

Outcomes of first-line osimertinib treatment for epidermal growth factor receptor-mutated non-small cell lung cancer in clinical practice settingsSemantic proximity Read ↗

The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis.Semantic proximity Read ↗

The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer.Semantic proximity Read ↗

Osimertinib making a breakthrough in lung cancer targeted therapySemantic proximity Read ↗

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.Semantic proximity Read ↗

A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.Semantic proximity Read ↗

Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.